[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. W. Marc Hertz Ph.D.", "age": 53, "title": "President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 842014, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Albert  Agro Ph.d.", "age": 58, "title": "Co-Founder & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 461099, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leanne M. Kelly", "age": 46, "title": "CFO & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 550930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cristina Gil White", "title": "Interim Chief Executive Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vipin  Kumar Chaturvedi Ph.D.", "age": 64, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.8227, "open": 0.788, "dayLow": 0.7105, "dayHigh": 0.805, "regularMarketPreviousClose": 0.8227, "regularMarketOpen": 0.788, "regularMarketDayLow": 0.7105, "regularMarketDayHigh": 0.805, "trailingPE": 0.012565271, "volume": 1490901, "regularMarketVolume": 1490901, "averageVolume": 3479840, "averageVolume10days": 17583660, "averageDailyVolume10Day": 17583660, "marketCap": 2359732, "fiftyTwoWeekLow": 0.302, "fiftyTwoWeekHigh": 134.68, "fiftyDayAverage": 0.51034, "twoHundredDayAverage": 6.299445, "currency": "USD", "enterpriseValue": -4112541, "floatShares": 2653439, "sharesOutstanding": 2927710, "sharesShort": 225823, "sharesShortPriorMonth": 143661, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0771, "heldPercentInsiders": 0.0035100002, "heldPercentInstitutions": 0.09788, "shortRatio": 0.15, "shortPercentOfFloat": 0.0773, "impliedSharesOutstanding": 3290660, "bookValue": 5.885, "priceToBook": 0.12185217, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -8278000, "trailingEps": 57.07, "lastSplitFactor": "1:13", "lastSplitDate": 1718668800, "enterpriseToEbitda": 0.492, "52WeekChange": -0.99320763, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.7171, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 6353000, "totalCashPerShare": 2.17, "ebitda": -8363000, "totalDebt": 141000, "quickRatio": 2.867, "currentRatio": 3.106, "debtToEquity": 2.988, "returnOnAssets": -0.82528, "returnOnEquity": -1.8906, "freeCashflow": -3866375, "operatingCashflow": -11215000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]